Zinzani, P. L. Et Al. 2023. Zilovertamab Vedotin Alone or in Combination With Nemtabrutinib in Aggressive and Indolent B-Cell Malignancies: Phase 2waveLINE-006Study. AMERICAN JOURNAL OF HEMATOLOGY .

Zinzani, P. L., Mayer, J., Benjamini, O., Berkovits, A., Glimelius, I., Stevens, D., ... Chaudhry, A.(2023). Zilovertamab Vedotin Alone or in Combination With Nemtabrutinib in Aggressive and Indolent B-Cell Malignancies: Phase 2waveLINE-006Study. AMERICAN JOURNAL OF HEMATOLOGY .

Zinzani, Pier Et Al. "Zilovertamab Vedotin Alone or in Combination With Nemtabrutinib in Aggressive and Indolent B-Cell Malignancies: Phase 2waveLINE-006Study," AMERICAN JOURNAL OF HEMATOLOGY , 2023

Zinzani, Pier L. Et Al. "Zilovertamab Vedotin Alone or in Combination With Nemtabrutinib in Aggressive and Indolent B-Cell Malignancies: Phase 2waveLINE-006Study." AMERICAN JOURNAL OF HEMATOLOGY , 2023

Zinzani, P. L. Et Al. (2023) . "Zilovertamab Vedotin Alone or in Combination With Nemtabrutinib in Aggressive and Indolent B-Cell Malignancies: Phase 2waveLINE-006Study." AMERICAN JOURNAL OF HEMATOLOGY .

@article{article, author={Pier Luigi Zinzani Et Al. }, title={Zilovertamab Vedotin Alone or in Combination With Nemtabrutinib in Aggressive and Indolent B-Cell Malignancies: Phase 2waveLINE-006Study}, journal={AMERICAN JOURNAL OF HEMATOLOGY}, year=2023}